LUNG Pulmonx Corp Forecast, Technical & Fundamental Analysis
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD)... Show more
LUNG is expected to report earnings to rise 6.67% to -25 cents per share on November 04
Q3'26
Est.
$-0.26
Q2'26
Beat
by $0.04
Q1'26
Beat
by $0.02
Q4'25
Beat
by $0.14
Q3'25
Beat
by $0.08
The last earnings report on July 29 showed earnings per share of -23 cents, beating the estimate of -28 cents. With 148.72K shares outstanding, the current market capitalization sits at 97.49M.
A.I.dvisor indicates that over the last year, LUNG has been loosely correlated with SRTS. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if LUNG jumps, then SRTS could also see price increases.
LUNG in downward trend: price may decline as a result of having broken its higher Bollinger Band on August 25, 2026
LUNG broke above its upper Bollinger Band on August 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 50 similar instances where the stock broke above the upper band. In of the 50 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for LUNG moved out of overbought territory on August 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LUNG as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for LUNG turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
LUNG moved above its 50-day moving average on July 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LUNG crossed bullishly above the 50-day moving average on August 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The 50-day moving average for LUNG moved above the 200-day moving average on August 26, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 170 cases where LUNG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.488) is normal, around the industry mean (10.849). P/E Ratio (0.000) is within average values for comparable stocks, (69.329). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.720). LUNG has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (1.082) is also within normal values, averaging (36.062).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
